The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.
Paolo Bossi
No relevant relationships to disclose
Loris De Cecco
No relevant relationships to disclose
Federica Perrone
No relevant relationships to disclose
Barbara Cortelazzi
No relevant relationships to disclose
Maria Cossu Rocca
No relevant relationships to disclose
Siano Marco
No relevant relationships to disclose
Andrea Sponghini
No relevant relationships to disclose
Cristiana Bergamini
No relevant relationships to disclose
Laura D. Locati
No relevant relationships to disclose
Aurora Mirabile
No relevant relationships to disclose
Roberta Granata
No relevant relationships to disclose
Carlo Resteghini
No relevant relationships to disclose
Silvana Pilotti
No relevant relationships to disclose
Silvana Canevari
No relevant relationships to disclose
Lisa F. Licitra
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono
Other Remuneration - Merck Serono